INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CAPR

Pomerantz LLP has filed a class action lawsuit against Capricor Therapeutics for alleged securities fraud related to its Deramiocel BLA submission to the FDA. The FDA's briefing documents revealed that Capricor altered its statistical analysis plan one day before data unblinding without FDA approval, leading the FDA to deem the analyses as 'post-hoc and exploratory.' Following the FDA's negative assessment on July 27, 2026, Capricor's stock plummeted 64%, and an advisory committee voted 9-3 against the drug's efficacy on July 30, 2026, causing an additional 36% stock decline.